Biden and Senator Sanders to highlight efforts lower cost of asthma
inhalers
Send a link to a friend
[April 03, 2024]
By Jarrett Renshaw
(Reuters) - U.S. President Joe Biden will host a White House event with
U.S. Senator Bernie Sanders on Wednesday to highlight their efforts to
cut the cost of inhalers for asthma suffers.
Sanders and other lawmakers in January criticized four manufacturers of
inhalers sold in the U.S. — AstraZeneca, Boehringer, Teva
Pharmaceuticals (TEVA.TA), and GSK (GSK.L), — over prices that were much
higher in the U.S. than in other countries.
The Biden administration has also sought to crack down on what it calls
falsely claimed patents in an effort to increase competition to lower
inhaler costs.
In March, three of the four companies decided to cap inhaler costs at
$35.
Asthma impacts 27 million Americans, including more than four million
children, the White House said in a preview of the event.
Biden has made lowering healthcare costs a key part of his 2024
re-election campaign.
Biden will also highlight successful efforts included in the Inflation
Reduction Act that placed a $2,000 cap on Medicare prescription drugs
and a separate $35 cap on insulin.
[to top of second column]
|
U.S. President Joe Biden is greeted by Senator Bernie Sanders (I-VT)
as he departs after delivering the State of the Union address at the
U.S. Capitol in Washington, D.C., March 7, 2024. REUTERS/Kevin
Lamarque/ File Photo
He will also use the event to push
to expand the number of Medicare drugs the federal government can
negotiate with pharmaceutical companies from 10 to 50, the White
House said.
Part of 2022's Inflation Reduction Act allows Medicare to negotiate
prices for prescription drugs that had been particularly expensive
for the federal health program that covers millions of Americans
aged 65 and older as well as the disabled.
(Reporting by Jarrett Renshaw; Editing by Mary Milliken and Michael
Perry)
[© 2024 Thomson Reuters. All rights reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |